NO984540L - Cytokrom P450 transduserende retrovirusvektorer - Google Patents

Cytokrom P450 transduserende retrovirusvektorer

Info

Publication number
NO984540L
NO984540L NO984540A NO984540A NO984540L NO 984540 L NO984540 L NO 984540L NO 984540 A NO984540 A NO 984540A NO 984540 A NO984540 A NO 984540A NO 984540 L NO984540 L NO 984540L
Authority
NO
Norway
Prior art keywords
cytochrome
retroviral vectors
capsules
transducing retroviral
treatment
Prior art date
Application number
NO984540A
Other languages
English (en)
Other versions
NO984540D0 (no
NO325392B1 (no
Inventor
Nzburg Walter H G
Peter Karle
Robert Michael Saller
Original Assignee
Bavarian Nordic Res Inst As
Gsf Forschungszentrum Umwelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8092560&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO984540(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic Res Inst As, Gsf Forschungszentrum Umwelt filed Critical Bavarian Nordic Res Inst As
Publication of NO984540L publication Critical patent/NO984540L/no
Publication of NO984540D0 publication Critical patent/NO984540D0/no
Publication of NO325392B1 publication Critical patent/NO325392B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C12N9/0079—Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19984540A 1996-03-27 1998-09-28 Kapsel som innkapsler et cytokrom P450 uttrykkende gen, farmasoytisk preparat som inneholder kapselen og anvendelse av kapselen til fremstilling av et medikament NO325392B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK35296 1996-03-27
PCT/EP1997/001585 WO1997035994A2 (en) 1996-03-27 1997-03-27 Cytochrome p450 transducing retroviral vectors

Publications (3)

Publication Number Publication Date
NO984540L true NO984540L (no) 1998-09-28
NO984540D0 NO984540D0 (no) 1998-09-28
NO325392B1 NO325392B1 (no) 2008-04-21

Family

ID=8092560

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19984540A NO325392B1 (no) 1996-03-27 1998-09-28 Kapsel som innkapsler et cytokrom P450 uttrykkende gen, farmasoytisk preparat som inneholder kapselen og anvendelse av kapselen til fremstilling av et medikament

Country Status (19)

Country Link
US (1) US6893634B1 (no)
EP (1) EP0892852B1 (no)
JP (1) JP4229982B2 (no)
AT (1) ATE309383T1 (no)
AU (1) AU713382B2 (no)
CA (1) CA2250173A1 (no)
CZ (1) CZ288074B6 (no)
DE (1) DE69730595D1 (no)
DK (1) DK0892852T3 (no)
ES (1) ES2253775T3 (no)
HU (1) HU221349B1 (no)
IL (1) IL125795A0 (no)
NO (1) NO325392B1 (no)
NZ (1) NZ331765A (no)
PL (1) PL188323B1 (no)
RU (2) RU2185821C2 (no)
SI (1) SI0892852T1 (no)
SK (1) SK282744B6 (no)
WO (1) WO1997035994A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187095C (zh) 1995-06-27 2005-02-02 巴法里安诺迪克有限公司 可生产病毒颗粒的被囊化细胞
US6540995B1 (en) 1996-03-27 2003-04-01 Bavarian Nordic Research Institute Gmbh Encapsulated cells producing cytochrome P450
JP4229982B2 (ja) 1996-03-27 2009-02-25 ババリアン・ノルディック・アクティーゼルスカブ シトクロムｐ４５０を形質導入するレトロウイルスベクター
WO2000017366A2 (en) * 1998-09-21 2000-03-30 Transgene S.A. Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug
GB0400443D0 (en) 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
AU1869900A (en) * 1999-01-04 2000-07-24 Ml Laboratories Plc P450/acetaminophen GDEPT for cancer treatment
GB9900009D0 (en) * 1999-01-04 1999-02-24 Ml Lab Plc Gene therapy
GB0010105D0 (en) * 2000-04-26 2000-06-14 Ml Lab Plc Cell ablation
AU2002336162A1 (en) * 2001-09-21 2003-04-01 Oxford Biomedica (Uk) Limited Pseudotyped retroviral vector system
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
MX377487B (es) 2015-05-29 2025-03-04 Univ Mexico Nac Autonoma Nanoparticulas biocataliticas cyp-p22 con actividad citocromo p450 para la activacion de profarmacos.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1215922A (en) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
WO1989011539A1 (en) 1988-05-17 1989-11-30 Sloan-Kettering Institute For Cancer Research Retroviral vector
WO1994029437A1 (en) 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
RU2039593C1 (ru) * 1993-06-22 1995-07-20 Ф.А. Чернышкова Катализатор для получения фенола и ацетона
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
RU2199585C2 (ru) 1994-09-02 2003-02-27 ГСФ-Форшунгсцентрум фюр Умвельт унд Гезундхайт ГмбХ Ретровирусная векторная конструкция, подвергающаяся промоторной конверсии, способ введения гомологичных или гетерологичных нуклеотидных последовательностей в человеческие или животные клетки in vitro и/или in vivo, рекомбинантная ретровирусная частица, фармацевтическая композиция для генной терапии
CN1187095C (zh) 1995-06-27 2005-02-02 巴法里安诺迪克有限公司 可生产病毒颗粒的被囊化细胞
EP0848757B1 (en) * 1995-09-06 2002-03-06 Austrian Nordic Biotherapeutics AG The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
JP4229982B2 (ja) 1996-03-27 2009-02-25 ババリアン・ノルディック・アクティーゼルスカブ シトクロムｐ４５０を形質導入するレトロウイルスベクター

Also Published As

Publication number Publication date
AU713382B2 (en) 1999-12-02
DK0892852T3 (da) 2006-03-06
HUP9904116A2 (hu) 2000-04-28
RU2223788C2 (ru) 2004-02-20
NZ331765A (en) 2000-02-28
CZ288074B6 (cs) 2001-04-11
DE69730595D1 (de) 2004-10-14
ES2253775T3 (es) 2006-06-01
HU221349B1 (en) 2002-09-28
SI0892852T1 (sl) 2006-04-30
HUP9904116A3 (en) 2001-01-29
NO984540D0 (no) 1998-09-28
CA2250173A1 (en) 1997-10-02
CZ305098A3 (cs) 1999-01-13
PL188323B1 (pl) 2005-01-31
SK282744B6 (sk) 2002-12-03
NO325392B1 (no) 2008-04-21
SK132398A3 (en) 1999-04-13
ATE309383T1 (de) 2005-11-15
AU2382797A (en) 1997-10-17
WO1997035994A2 (en) 1997-10-02
JP2000509249A (ja) 2000-07-25
JP4229982B2 (ja) 2009-02-25
EP0892852A2 (en) 1999-01-27
IL125795A0 (en) 1999-04-11
WO1997035994A3 (en) 1997-11-20
US6893634B1 (en) 2005-05-17
EP0892852B1 (en) 2005-11-09
RU2185821C2 (ru) 2002-07-27
PL329071A1 (en) 1999-03-15

Similar Documents

Publication Publication Date Title
IL112664A0 (en) 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
PY950041A (es) Compuesto de 1- fenil 3-dimetilamino- propano a procedimientos para su preparacion y a la aplicacion de estas sustancias en farmacologia
TR200001544T2 (tr) Yeni bileşikler.
EE200000320A (et) Uudsed ühendid
SE9704544D0 (sv) Novel compounds
ATE224888T1 (de) Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel
IL147220A0 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containing the same
CA2310888A1 (en) Monoclonal human natural antibodies
ZA965752B (en) Triphenylethylenes, process for their production, pharmaceutical preparations that contain these triphenylethylenes as well as their use for the production of pharmaceutical agents.
IL112667A0 (en) 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
NO902411D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-n-propylaminer.
NO162238C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,4-dihydro-4-oksonaftyridinderivater.
NO984540D0 (no) Cytokrom P450 transduserende retrovirusvektorer
NZ508585A (en) Metabolites of ecteinascidin 743
NO165922C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive estere av hexahydro-8-hydroxy-2,6-methano-2h-kinolizin-3-(4h)-on og beslektede forbindelser.
WO1991015512A3 (en) Hiv envelope polypeptides
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
IL112668A0 (en) 4-amino 6-substituted mycophenolic acid and derivatives thereof, their preparation and pharmaceutical compositions containing them
ZA986336B (en) Medicaments comprising polyhydroxybutylpyrazines novel polyhydroxybutylpyrazines and their preparation
IL112666A0 (en) 4-amino derivatives of 5-substituted mycophenolic acid, their preparation and pharmaceutical compositions containing them
WO2000017366A3 (en) Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug
BR9710629A (pt) Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto
ZA928127B (en) Use of substituted pyrrolidines, some of which are known, as medicaments, new active substances and processes for their preparation.
NO885406D0 (no) Fremgangsmaate for fremstilling av 4-heteroaryl-1,3-benzodiazepiner og 2-substituerte-alfa-(hetero-aryl)benzenetanaminer og anvendelse derav som medikamenter.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees